AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
DELRAY BEACH, Fla., Jan. 06, 2021 — AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that the Company will be participating in the virtual H.C. Wainwright BioConnect 2021 Conference.
James Sapirstein, President & CEO of AzurRx BioPharma, will be participating in virtual one-on-one meetings with registered investors and pharmaceutical companies. Mr. Sapirstein will be available to provide an overview of the Company’s business and clinical development programs and discuss anticipated 2021 milestones.